Stroke:头颈部感染的脑静脉血栓的患者可以用肝素抗凝吗?

2016-05-31 phylis 译 MedSci原创

背景:头部或颈部局部感染是脑静脉血栓形成的原因。肝素治疗感染性脑静脉血栓是有争议的。研究者调查是否这种治疗与颅内出血性并发症和不良的预后相关。方法:研究者从624个脑静脉血栓患者的前瞻性队列研究中提取数据。研究者比较有无头颈部感染进行抗凝和不抗凝治疗,患者死亡或残疾及新脑出血发生的差异。结果:604/624例患者有资格参与这项研究。57例(9.4%)患者头部或颈部感染。比较感染和非感染患者之间的数

背景:头部或颈部局部感染是脑静脉血栓形成的原因。肝素治疗感染性脑静脉血栓是有争议的。研究者调查是否这种治疗与颅内出血性并发症和不良的预后相关。

方法:研究者从624个脑静脉血栓患者的前瞻性队列研究中提取数据。研究者比较有无头颈部感染进行抗凝和不抗凝治疗,患者死亡或残疾及新脑出血发生的差异。

结果:604/624例患者有资格参与这项研究。57例(9.4%)患者头部或颈部感染。比较感染和非感染患者之间的数据,两组间肝素治疗剂量是相似的(82.5% vs 83.7%)。感染组患者更易出现新的脑出血(12.3% vs 5.3%;P = 0.04),感染组和非感染组死亡和残疾的患者没有差异(15.8% vs 13.7%)。头颈部感染的患者,不管是否接受肝素治疗,新发脑出血的频率与不良预后没有差异。

结论:感染患者更易出现新发脑出血。肝素治疗剂量似乎并没有影响新的颅内出血的风险或不良的临床预后,但是接受抗凝治疗的患者太少,头颈部感染脑静脉血栓形成患者应用肝素的是否安全性得不出确切的结论。

原始出处:

Zuurbier SM, Coutinho JM, et al. Clinical Outcome of Anticoagulant Treatment in Head or Neck Infection-Associated Cerebral Venous Thrombosis. Stroke. 2016 May.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=147571, encodeId=203214e571c2, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Oct 13 10:58:27 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955234, encodeId=6da7195523450, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 07 16:37:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697319, encodeId=530a169e319df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jun 06 17:37:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491773, encodeId=4fc41491e73f5, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589697, encodeId=6c42158969ef8, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-10-13 ylzr123

    好文值得点赞!继续关注学习。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=147571, encodeId=203214e571c2, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Oct 13 10:58:27 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955234, encodeId=6da7195523450, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 07 16:37:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697319, encodeId=530a169e319df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jun 06 17:37:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491773, encodeId=4fc41491e73f5, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589697, encodeId=6c42158969ef8, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2017-03-07 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=147571, encodeId=203214e571c2, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Oct 13 10:58:27 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955234, encodeId=6da7195523450, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 07 16:37:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697319, encodeId=530a169e319df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jun 06 17:37:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491773, encodeId=4fc41491e73f5, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589697, encodeId=6c42158969ef8, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-06 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=147571, encodeId=203214e571c2, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Oct 13 10:58:27 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955234, encodeId=6da7195523450, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 07 16:37:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697319, encodeId=530a169e319df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jun 06 17:37:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491773, encodeId=4fc41491e73f5, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589697, encodeId=6c42158969ef8, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 wshxjq
  5. [GetPortalCommentsPageByObjectIdResponse(id=147571, encodeId=203214e571c2, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Oct 13 10:58:27 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955234, encodeId=6da7195523450, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 07 16:37:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697319, encodeId=530a169e319df, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jun 06 17:37:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491773, encodeId=4fc41491e73f5, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589697, encodeId=6c42158969ef8, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jun 02 10:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]

相关资讯

STM:新型人工合成肝素抗凝剂拮抗药临床疗效显著

以肝素为基本成分的抗凝药物被广泛用于预防外科手术过程中的血液凝固和治疗血栓栓塞性疾病。肝素是间接抗凝剂,通过与抗凝血酶结合,加快对活化的Ⅹa因子和凝血酶的抑制作用,从而达到抗凝的效果。然而,我们需要对这些与抗凝剂相关的出血风险进行持续的监测,并使用合适的解毒剂中和其抗凝作用。尤其是在大型的外科手术和体外循环之后,对防止致命性的血栓形成具有重要意义。鱼精蛋白是唯一一个被临床证实的肝素解毒剂,现在却已

HEAT-PPCI反对军团,又添一将

瑞典SCAAR注册研究发现,在接受直接经皮冠状动脉介入(PCI)的ST段抬高型心肌梗死(STEMI)患者中,使用比伐卢定、肝素或血小板糖蛋白Ⅱb/Ⅲa受体抑制剂(GPI),早期支架内血栓发生率无显著差异,均处于较低水平。研究中,比伐卢定组为16860例(4%同时接受了紧急GPI治疗)、GPI组为11392例(几乎所有患者均同时应用肝素)、肝素组为3264例。结果发现,术后30天,三组的确诊支架

蛇毒让肝素治疗的患者手术更安全

对一些心肺疾病或手术,使用肝素等药物预防血栓已经是司空见惯的诊疗常规,但是使用药物抗凝的患者在术中止血就成了大问题,抗凝或抗血栓显然会导致血凝块不易形成,伤口不易愈合,出血风险增大。不过研究者已经找到了解决该问题的新方法。目前的医疗方案中,医生可以采取以下几种方法来减少使用肝素和其他血液稀释剂的患者的术中出血,包括压迫、缝合线、止血纱等。但是这些措施都存在潜在严重风险,一些会给患者带来毒副作用,导

抗栓新药:几家欢喜几家愁

抗栓新药:几家欢喜几家愁 ATLANTIC研究对抗血小板治疗的影响 方唯一教授介绍,PLATO研究已证实在处理ACS包括ST段抬高型心肌梗死(STEMI)患者时,替格瑞洛优于氯吡格雷。在此基础上,ATLANTIC研究进一步探讨更早(院前)应用替格瑞洛是否比导管室应用更好。虽然,研究在主要有效终点上(心电图ST段回落和首次造影梗死相关动脉TIMI血流Ⅲ级比例)未达统计学差异,但次要终

JACC:TAVR过程中,比伐卢定并不优于肝素的效果

抗凝治疗是经导管主动脉瓣置换术(TAVR)的必需程序。虽然一个最佳方案尚未确定,但主要用肝素。直接凝血酶抑制比伐卢定可能是在此过程中用于抗血凝剂一种有效的替代肝素药物。 本研究的目的是确定是否比伐卢定可以替代肝素作为接受TAVR的患者的抗凝血剂。共有802例主动脉瓣狭窄患者被随机分配接受经股TAVR比伐卢定 vs 肝素。2个主要终点是48小时内或出院前严重出血事件(以先发生为准)和30天

TCT2014:多专家讨论中国BRIGHT研究

在TCT 2014年会上,沈阳军区总医院韩雅玲教授公布了中国BRIGHT试验结果。此项随机试验对比伐卢定、普通肝素以及肝素联合替罗非班进行了比较。该实验初步结果曾于中国介入心脏病学大会上公布。 BRIGHT试验结果显示,与肝素和肝素联合替罗非班组相比,比伐卢定组患者的整体出血事件分别减少50%和60%(P=0.041和0.001)。比伐卢定、普通肝素以及肝素联合替罗非班组的支架内血栓形成发生率分